Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Ultima Vez Modificado: 1 de noviembre del 2001
Last Updated: 2001-01-31 13:00:35 EST (Reuters Health) - Patients who have undergone bone marrow transplantation for hematologic malignancies face a higher risk of developing subsequent solid cancers, according to a report in the January 15th issue of the Journal of Clinical Oncology.
Second neoplasms occur at an increased rate after chemotherapy and irradiation, the authors note, but whether the regimens employed in association with bone marrow transplantation (BMT) contribute to the formation of subsequent solid cancers is uncertain.
Dr. Smita Bhatia and colleagues from City of Hope National Medical Center, Duarte, California, evaluated the role of pretransplantation therapeutic exposures and transplant conditioning regimens in the development of subsequent nonhematopoietic malignancies in 2129 patients who had undergone BMT.
Twenty-nine patients developed invasive solid tumors during the years after BMT, a rate more than double that expected in the general population, the authors report. By 5 years posttransplant, 1.6% of patients had developed second tumors, and by 10 years posttransplant, the cumulative incidence had reached 6.1%.
New malignancies were much more common after allogeneic BMT (6.4% at 10 years) than after autologous BMT (1.6% at 10 years), the report indicates, and patients younger than 34 years were 5.3 times more likely than the general population to develop solid malignancies.
Compared with the general population, BMT patients faced a 13-fold increased risk of cervical cancer or thyroid cancer, a 27.7-fold higher risk of liver cancer, and a 53.3-fold increased risk of cancer of the oral cavity. Patients who had received total body irradiation tended to develop more secondary liver, thyroid, and oral cavity cancers than did patients who did not receive TBI, the results indicated.
In contrast, the treatments surrounding the BMT, the presence of acute or chronic graft-versus-host disease, and various demographic variables showed no association with the development of subsequent solid cancers. "The contribution of treatment received before or during transplantation remains unclear," the authors conclude.
In comments to Reuters Health, Dr. Bhatia said "it is absolutely imperative that all patients receiving BMT (irrespective of the type of conditioning) be followed long term (for life) for second malignancies and other late effects."
Dr. Bhatia acknowledged, "The number of patients with second cancers was small; hence, the power might not have been adequate to detect the effect of pretransplant chemotherapy."
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults